Premium
Validity and clinimetric properties of the S pinal A lignment and R ange of M otion M easure in children with cerebral palsy
Author(s) -
Chen ChiaLing,
Wu Katie P H,
Liu WenYu,
Cheng HsinYi Kathy,
Shen IHsuan,
Lin KehChung
Publication year - 2013
Publication title -
developmental medicine and child neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.658
H-Index - 143
eISSN - 1469-8749
pISSN - 0012-1622
DOI - 10.1111/dmcn.12153
Subject(s) - cerebral palsy , range of motion , gross motor function classification system , medicine , minimal clinically important difference , construct validity , physical therapy , psychology , surgery , randomized controlled trial , patient satisfaction
Aim The aim of this study was to assess the validity, responsiveness, and clinimetric properties of the S pinal A lignment and R ange of M otion M easure ( SAROMM ) in children with cerebral palsy ( CP ). Method Sixty‐two children with CP (40 males, 22 females) with a median age of 3 years and 11 months (range 1–6y) and their caregivers participated in this study. Among the children, 56 had spastic CP while six had non‐spastic CP ; 53 had bilateral CP , while nine had unilateral limb involvement. Thirty‐three children were classified as G ross M otor F unction C lassification S ystem ( GMFCS ) levels I to III and 23 as levels IV or V . Fifty‐six children (90%) received regular rehabilitation by means of regular physical or occupational therapy (50% once or twice per week and 40% more than two times per week) and six children (10%) received irregular rehabilitation (less than once a week). Construct validity was determined by assessing the strength of the correlation between the spinal alignment SAROMM ( SAROMM ‐ SA ), the range of motion SAROMM ( SAROMM ‐ ROM ), and the total SAROMM ( SAROMM ‐total), and construct measures, including the 66‐item G ross M otor F unction M easure ( GMFM ‐66) and F unctional I ndependence M easures for C hildren ( W ee FIM ), at baseline and at 6‐months follow‐up. Responsiveness was examined using effect size. Minimal detectable change ( MDC ) at the 90% confidence level ( MDC 90) and minimal clinically important difference ( MCID ) were analysed. Results The SAROMM with the GMFM ‐66 and W ee FIM had fair to good construct validity. The effect size values of all SAROMM scales were 0.24 to 0.48. The MDC 90 values and MCID range were 1.43 and 0.47 to 1.67 for the SAROMM ‐ SA , 3.12 and 3.68 to 4.07 for the SAROMM ‐ ROM , and 3.22 and 4.53 to 4.62 for the SAROMM ‐total. Interpretation The clinimetric properties of the SAROMM allow clinicians to determine whether a change in SAROMM score represents a clinically meaningful change.